医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
24期
396-396
,共1页
尿酸%心肌梗死%预后
尿痠%心肌梗死%預後
뇨산%심기경사%예후
目的:探讨不同水平的血尿酸对急性ST段抬高型心肌梗死(STEMI)的发病严重程度及判断患者预后的作用。方法:收集本院2013年1月1日至2013年12月31日收治的102例STEMI患者,根据血尿酸(SUA)水平分组:正常组(SUA<420umol/l)和高尿酸血症组(SUA≥420umol/l),并比较患者在BNP、LVEF、CKMB等心梗严重指标以及心梗并发症的发生率(恶性心律失常、猝死)等预后指标。结果:两组患者在BNP、LVEF、CKMB以及心梗并发症发生率上存在显著差异(P<0.05)。结论:对于STEMI患者来说,SUA水平可作为判断患者心梗严重程度及预后的重要参考指标。
目的:探討不同水平的血尿痠對急性ST段抬高型心肌梗死(STEMI)的髮病嚴重程度及判斷患者預後的作用。方法:收集本院2013年1月1日至2013年12月31日收治的102例STEMI患者,根據血尿痠(SUA)水平分組:正常組(SUA<420umol/l)和高尿痠血癥組(SUA≥420umol/l),併比較患者在BNP、LVEF、CKMB等心梗嚴重指標以及心梗併髮癥的髮生率(噁性心律失常、猝死)等預後指標。結果:兩組患者在BNP、LVEF、CKMB以及心梗併髮癥髮生率上存在顯著差異(P<0.05)。結論:對于STEMI患者來說,SUA水平可作為判斷患者心梗嚴重程度及預後的重要參攷指標。
목적:탐토불동수평적혈뇨산대급성ST단태고형심기경사(STEMI)적발병엄중정도급판단환자예후적작용。방법:수집본원2013년1월1일지2013년12월31일수치적102례STEMI환자,근거혈뇨산(SUA)수평분조:정상조(SUA<420umol/l)화고뇨산혈증조(SUA≥420umol/l),병비교환자재BNP、LVEF、CKMB등심경엄중지표이급심경병발증적발생솔(악성심률실상、졸사)등예후지표。결과:량조환자재BNP、LVEF、CKMB이급심경병발증발생솔상존재현저차이(P<0.05)。결론:대우STEMI환자래설,SUA수평가작위판단환자심경엄중정도급예후적중요삼고지표。
Objective: To explore disease severity and prognosis of patients with acute ST segment elevation myocardial infarction (STEMI) with different levels of serum uric acid. Methods: 102 cases of NSTEMI were colected in our hospital from January 1, 2013 to December 31, 2013, according to the blood uric acid (SUA) level, they were separate into different groups: normal group (SUA < 420umol/l) and hyperuricemia group (SUA = 420umol/l), compared with BNP, LVEF, CKMB mark which is the incidences of severe myocardial infarction, and prognostic index referred to the probability of complications (such as sudden death, malignant arythmie.Results: the two groups of patients have significant differences in BNP, LVEF, the rate of CKMB and Mi complications (P < 0.05).Conclusion: for patients with STEMI, SUA can serve as an important reference index for judging the severity and prognosis of patients with myocardial infarction.